Elevance Health

ELV declined 1.9% to close at $431.32, primarily driven by profit-taking following the recent surge. The company reported strong Q3 2026 results with revenue of $51.43B (+1.42% year-over-year), net profit up 14.8% YoY, and EPS of $6.27 (+17.86% YoY). Management also raised 2026 full-year EPS guidance to at least $29, which initially lifted the stock to as high as $449.60 in the pre-market session at 04:02 ET. Despite TD Cowen and Guggenheim maintaining buy ratings with price targets of $495 and $485 respectively, intraday momentum faded and the stock retreated to $429.77 by after-hours close. The company's CFO sold over $4.6M in shares recently, potentially adding to investor caution. Nonetheless, ELV trades near its 52-week high of $450.69 achieved on October 21, only -4.3% below the peak, with year-to-date gains of 21.76% and price action above its 60-day moving average.

ELV retreated 1.2% to $439.95 during regular trading hours despite pre-market strength that had lifted the stock to $449.70, as profit-taking pressures materialized following strong Q3 earnings and management's upward guidance revision. The company delivered Q3 EPS of $6.27 (up 17.86% year-over-year), revenue of $51.43B (up 1.42% YoY), and net income growth of 14.8%, while lifting full-year EPS guidance to at least $29; TD Cowen maintained a Buy rating with a $495 target, and Guggenheim kept its Buy stance at a $485 target. The stock subsequently rebounded in after-hours trading to $446.68, trading within 2.4% of its 52-week high reached on October 21st and maintaining a year-to-date gain of 24.19%, well above its 60-day moving average of $413.94. CFO's recent sale of $4.6M+ in shares may reflect profit-taking at elevated levels, while current valuations at 18.6x P/E suggest the market has already priced in much of the near-term upside potential.

ELV.US pulled back under pressure today, declining 1.38% to close at $434.13, with intraday losses reaching 2.3%, primarily driven by profit-taking following better-than-expected Q3 results. The company reported third-quarter revenue of $51.43 billion, EPS of $6.27 beating expectations, and net income rising 13% year-over-year to $1.34 billion, prompting a full-year EPS guidance raise to at least $29; however, the stock retreated sharply from the intraday high of $450.69 (a new 52-week peak reached in pre-market trading) to a low of $426.13 during regular hours, signaling that the market has already priced in the positive results. More concerning is the persistent medical cost pressure evident in the prior two quarters, with net income declining 16% and 19% year-over-year respectively, though Q3's recovery suggests some moderation. From a valuation perspective, ELV has gained 22.55% year-to-date and currently trades just 3.67% below its 52-week high, well above its 60-day moving average of $402.81, suggesting elevated valuations may be limiting further upside momentum.

Elevance Health surged to its 52-week high of $440.67 in intraday trading, gaining over 2.3% as investors positioned ahead of the company's Q3 earnings release, with market sentiment bolstered by optimism around its Medicare Advantage business trajectory. Guggenheim maintained a Buy rating with a $460 price target, implying roughly 6% upside from current levels. The stock has climbed 24.26% year-to-date, though it now sits at elevated valuations near all-time highs. A post-market pullback to $434 signals some profit-taking momentum after the intraday spike. However, the stock faces a near-term headwind from consecutive quarter earnings weakness—Q2 EPS declined 13.08% year-over-year while net profit fell 16.06%—raising questions about whether the current price level has fully accounted for softer fundamentals. At a PE of 19.23x, valuation appears reasonable in isolation, but the gap between robust price momentum and moderating profit growth warrants close monitoring as the company reports Q3 results.

ELV rose marginally 0.46% to $430.23, displaying a V-shaped intraday pattern that alternated pre-market gains with a sharp gap-down at market open and subsequent rebound. The stock climbed to $431.36 in pre-market trading, then gapped down to $425.76 at the regular session open before recovering to close at $430.23; post-market activity remained essentially flat. Conflicting catalysts weigh on investor sentiment: earnings show Q2 EPS of $6.71, down 13% year-over-year, with net profit falling 16% despite operating revenue of $50.47B expanding modestly at 1.4%. On the positive side, Guggenheim maintained its Buy rating and raised the price target to $460, offering support; conversely, Vontobel's recent position cut signals institutional concerns. Positioned near recent highs, ELV has gained 21.45% year-to-date and hovers just 1.38% below its 52-week high, leaving limited room for further appreciation.